24.28
3.76%
0.88
Handel nachbörslich:
24.28
Septerna Inc Aktie (SEPN) Neueste Nachrichten
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Septerna initiated with an Overweight at JPMorgan - Yahoo Finance
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering - ForexTV.com
Ra Capital Management buys $75 million in Septerna stock By Investing.com - Investing.com Australia
Ra Capital Management buys $75 million in Septerna stock - Investing.com
IPO Radar: Septerna, Swiggy and Horizon Robotics - The Armchair Trader
Septerna sees $11.7 million in stock purchases by Third Rock Ventures - Investing.com South Africa
IPO Roundup: Brazil Potash, Septerna and more (NYSEARCA:IPO) - Seeking Alpha
Sentiment for IPO Market in 2025 Continues to Improve - TheStreet
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Septerna’s GPCRs draw strong demand in $288M IPO - BioCentury
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Hedge Funds, Asset Managers Turn Dollar Bulls on Election Risks - Yahoo Finance
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
Septerna Shares Rise 29% on First Trading Day - MarketWatch
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - MedCity News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut - KFGO
Septerna Shares Jump 42% After IPO Shows Biotech Still Hot - AllSides
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):